津药药业子公司氯化钾注射液获新规格批准

财中社11-25 15:55

财中社11月25日电津药药业（600488）发布关于子公司药品新增规格及通过仿制药一致性评价的公告。公告指出，公司子公司湖北公司近日收到国家药品监督管理局核准的氯化钾注射液的《药品补充申请批准通知书》，批准该药品新增10ml:1.5g规格，并通过仿制药质量和疗效一致性评价。该药品用于治疗和预防低钾血症，适用于无法口服补钾的情况。截至目前，湖北津药在氯化钾注射液项目上已累计投入研发费用约557万元。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2486742487?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-25 15:55","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2486742487","market":"sh","top_or_hot":-1,"title":"津药药业子公司氯化钾注射液获新规格批准","media":"财中社","content":"<div>\n<p>财中社11月25日电津药药业（600488）发布关于子公司药品新增规格及通过仿制药一致性评价的公告。公告指出，公司子公司湖北公司近日收到国家药品监督管理局核准的氯化钾注射液的《药品补充申请批准通知书》，批准该药品新增10ml:1.5g规格，并通过仿制药质量和疗效一致性评价。该药品用于治疗和预防低钾血症，适用于无法口服补钾的情况。截至目前，湖北津药在氯化钾注射液项目上已累计投入研发费用约557万元。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125160912abdd3866&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>津药药业子公司氯化钾注射液获新规格批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n津药药业子公司氯化钾注射液获新规格批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-25 15:55 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125160912abdd3866&s=b><strong>财中社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>财中社11月25日电津药药业（600488）发布关于子公司药品新增规格及通过仿制药一致性评价的公告。公告指出，公司子公司湖北公司近日收到国家药品监督管理局核准的氯化钾注射液的《药品补充申请批准通知书》，批准该药品新增10ml:1.5g规格，并通过仿制药质量和疗效一致性评价。该药品用于治疗和预防低钾血症，适用于无法口服补钾的情况。截至目前，湖北津药在氯化钾注射液项目上已累计投入研发费用约557万元。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125160912abdd3866&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125160912abdd3866&s=b","article_id":"2486742487","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125160912abdd3866&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2486742487","pubTimestamp":1732521353,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"公告指出，公司子公司湖北公司近日收到国家药品监督管理局核准的氯化钾注射液的《药品补充申请批准通知书》，批准该药品新增10ml:1.5g规格，并通过仿制药质量和疗效一致性评价。截至目前，湖北津药在氯化钾注射液项目上已累计投入研发费用约557万元。根据米内网数据，2022年和2023年氯化钾注射液的国内销售额分别为6.12亿元和6.61亿元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600488":"津药药业","BK0028":"国家队","BK0012":"证金概念","BK0239":"医药制造","BK0102":"重组"},"translate_title":"Potassium Chloride Injection, a subsidiary of Jinyao Pharmaceutical, was approved for new specifications","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600488":1},"content_text":"财中社11月25日电津药药业（600488）发布关于子公司药品新增规格及通过仿制药一致性评价的公告。公告指出，公司子公司湖北公司近日收到国家药品监督管理局核准的氯化钾注射液的《药品补充申请批准通知书》，批准该药品新增10ml:1.5g规格，并通过仿制药质量和疗效一致性评价。该药品用于治疗和预防低钾血症，适用于无法口服补钾的情况。截至目前，湖北津药在氯化钾注射液项目上已累计投入研发费用约557万元。根据米内网数据，2022年和2023年氯化钾注射液的国内销售额分别为6.12亿元和6.61亿元。新增规格和通过一致性评价将有助于丰富患者用药选择，扩大市场份额并提升市场竞争力，但也需关注药品研发、生产和销售可能受到的政策和市场环境影响。2024年前三季度，津药药业实现收入25.72亿元，归母净利润1.87亿元。文章来源：财中社原标题：津药药业子公司氯化钾注射液获新规格批准","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2486742487"}